Enhancing Diagnosis with Genetic Insights
On Rare Disease Day, Strand Life Sciences, a subsidiary of Reliance Industries, introduced the StrandOmics Portal, an online platform designed to improve the diagnosis of rare diseases. This cutting-edge tool provides clinicians with access to genetic variant information, enabling a comprehensive case review for faster and more accurate diagnoses.
Subsidized Genetic Testing for Patients in Need
As reported by economictimes, to support individuals from economically disadvantaged backgrounds, Strand Life Sciences has also announced subsidized genetic testing. This initiative aims to ensure that more patients can benefit from advanced genetic diagnostics, regardless of financial constraints.
Empowering Doctors with Deeper Genetic Insights
The StrandOmics Portal enhances clinical decision-making by providing doctors with detailed genetic insights. It allows for an independent review of a broader range of genetic variants and fosters better collaboration among specialists, particularly in prenatal diagnosis.
Commitment to Innovation in Rare Disease Research
Dr. Ramesh Hariharan, CEO & Co-Founder of Strand Life Sciences, emphasized the company’s dedication to continuous innovation.
“We will continue to innovate and invest in tools like the StrandOmics Portal to empower doctors in their fight against rare diseases,” he stated.
With the launch of this advanced platform, Strand Life Sciences is making a major move in rare disease diagnosis. It aims to make genetic testing more accessible.